Patients with NPC1 suffer from a severe life-limiting disease, the potential risks of TNF therapy (demyelination and increased infection susceptibility) must be balanced against the improvement in quality of life due to effective IBD therapy and symptom control. Here, TNF is linked to inflammatory bowel disease.